Charles Schwab
EWTX icon

Charles Schwab’s Edgewise Therapeutics EWTX Stock Holding History

Charles Schwab’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.2M Buy
620,532
+24,222
+4% +$835K ﹤0.01% 1696
2026
Q1 		$18.8M Sell
596,310
-15,074
-2% -$435K ﹤0.01% 1777
2025
Q4 		$15.2M Buy
611,384
+13,781
+2% +$277K ﹤0.01% 1921
2025
Q3 		$9.69M Buy
597,603
+18,499
+3% +$262K ﹤0.01% 2134
2025
Q2 		$7.59M Buy
579,104
+57,843
+11% +$834K ﹤0.01% 2145
2025
Q1 		$11.5M Sell
521,261
-16,098
-3% -$422K ﹤0.01% 1891
2024
Q4 		$14.3M Buy
537,359
+15,273
+3% +$486K ﹤0.01% 1859
2024
Q3 		$13.9M Sell
522,086
-49,111
-9% -$977K ﹤0.01% 1884
2024
Q2 		$10.3M Buy
571,197
+74,035
+15% +$1.29M ﹤0.01% 2037
2024
Q1 		$9.07M Buy
497,162
+166,103
+50% +$2.64M ﹤0.01% 2032
2023
Q4 		$3.62M Buy
331,059
+200
+0.1% +$1.4K ﹤0.01% 2444
2023
Q3 		$1.9M Buy
330,859
+19,987
+6% +$136K ﹤0.01% 2616
2023
Q2 		$2.41M Buy
310,872
+16,561
+6% +$140K ﹤0.01% 2495
2023
Q1 		$1.96M Sell
294,311
-2,564
-0.9% -$23.8K ﹤0.01% 2527
2022
Q4 		$2.65M Buy
296,875
+94,102
+46% +$882K ﹤0.01% 2473
2022
Q3 		$2M Buy
202,773
+87,521
+76% +$884K ﹤0.01% 2586
2022
Q2 		$918K Sell
115,252
-30,053
-21% -$227K ﹤0.01% 2831
2022
Q1 		$1.41M Buy
145,305
+4,910
+3% +$63.2K ﹤0.01% 2745
2021
Q4 		$2.15M Buy
140,395
+56,285
+67% +$1.01M ﹤0.01% 2688
2021
Q3 		$1.4M Buy
84,110
+3,036
+4% +$54.9K ﹤0.01% 2772
2021
Q2 		$1.73M Buy
+81,074
New +$2.22M ﹤0.01% 2762

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Charles Schwab's EWTX Position: Q2 2026 in Review

Charles Schwab increased its Edgewise Therapeutics (EWTX) stake by 4.1% in Q2 2026, buying an estimated $835K and bringing the position to 620,532 shares worth $25.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1696.

Charles Schwab first reported a position in EWTX in Q2 2021 and has held it in 21 quarters since. 223 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Charles Schwab held 620,532 shares of Edgewise Therapeutics worth $25.2M as of Q2 2026.
  • Charles Schwab bought 24,222 Edgewise Therapeutics shares in Q2 2026, an estimated $835K.
  • Edgewise Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #1696 holding.
  • Charles Schwab first reported a position in Edgewise Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • 223 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.